Merck Boosts Outlook As Q3 Results Top Estimates

RTTNews | 817 ngày trước

(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK) reported Thursday profit for the third quarter that declined 29 percent from last year, hurt by hefty increase in R&D expenses, despite 14 percent sales growth. However, both adjusted earnings per share and quarterly sales topped analysts' estimates.

"Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers," said Robert Davis, President and CEO.

For the third quarter, net income attributable to the company decreased 29 percent to $3.24 billion or $1.28 per share from $4.57 billion or $1.80 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $1.85 per share, compared to $1.75 per share in the year-ago quarter.

On average, 17 analysts polled by Thomson Reuters expected the company to report earnings of $1.71 per share for the quarter. Analysts' estimates typically exclude special items.

Worldwide sales for the quarter increased 14 percent to $14.96 billion from $13.15 billion in the same quarter last year. The Street was looking for revenues of $14.08 billion for the quarter. Excluding the impact from foreign exchange, sales increased 18 percent.

Lagevrio sales were $436 million. Worldwide sales growth, excluding Lagevrio, was 10 percent. Growth excluding Lagevrio and foreign exchange impact was 14 percent. Sales growth was favorably impacted by COVID-19 recovery.

Pharmaceutical sales increased 13 percent to $12.96 billion, with KEYTRUDA sales growing 20 percent or 26 percent in constant currency, to $5.43 billion and GARDASIL / GARDASIL 9 increasing 15 percent or 20 percent in constant currency, to $2.29 billion, while JANUVIA / JANUMET sales declined 15 percent or 9 percent in constant currency, to $1.13 billion from last year.

Animal Health sales decreased 3 percent to $1.37 billion last year. Excluding the impact from foreign exchange, sales increased 4 percent.

Looking ahead to fiscal 2022, Merck now projects earnings in a range of $5.68 to $5.73 per share and adjusted earnings in a range of $7.32 to $7.37 per share on sales growth of 20 to 21 percent and revenues between $58.5 billion and $59.0 billion, including a negative impact from foreign exchange of approximately 4 percent.

Previously, the company expected earnings in the range of $5.89 to $5.99 per share and adjusted earnings in the range of $7.25 to $7.35 per share on sales growth of 18 to 20 percent and revenues between $57.5 billion and $58.5 billion

Analysts expect annual earnings of $7.34 per share on revenues of $58.51 billion for the year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Thẻ: MRK

Merck Q2 Results Top Estimates, But Slashes FY24 Earnings Outlook

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the second quarter compared to a loss last year, reflecting improved gross margins and a 7 percent sales growth. Both adjusted earnings per share and quarterly sales topped analysts' estimates. However, the company slashed its adjusted earnings guidance for the full-year 2024.

RTTNews | 175 ngày trước

Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults

Ligand Pharmaceuticals Inc. (LGND) announced Tuesday that its collaborator Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.

RTTNews | 217 ngày trước

Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients

Merck & Co. Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Thursday it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1.

RTTNews | 292 ngày trước

Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy

Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 as determined by a validated test.

RTTNews | 344 ngày trước

Merck Guides FY24 EPS Above Estimates As Q4 Results Top Estimates

Biopharmaceutical company Merck reported Thursday a net loss for the fourth quarter compared to a profit last year, hurt by hefty charge, despite 6 percent sales growth. However, both adjusted earnings per share and quarterly sales topped analysts' estimates.

RTTNews | 355 ngày trước

Merck Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates

Biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, reported Thursday a net loss attributable to the company for the fourth quarter of $1.23 billion or $0.48 per share, compared to net income of $3.02 billion or $1.18 per share in the prior-year quarter.

RTTNews | 355 ngày trước

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.

RTTNews | 396 ngày trước

Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints

Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, and Japan's Eisai Co. Ltd. (ESALY.PK, ESALF.PK) announced Friday that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair proficient (pMMR)/not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)/MSI-H.

RTTNews | 410 ngày trước

EURUSD	1.04017	GBPUSD	1.23193	AUDUSD	0.62545
USDJPY	155.862	USDCAD	1.43513	USDCHF	0.90712